Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic inflammatory polyneuritis and neuropathies

K V Toyka1, H P Hartung

  • 1Department of Neurology, Bayerische Julius-Maximilians-Universität, Würzburg, Germany.

Current Opinion in Neurology
|June 1, 1996
PubMed
Summary

Recent advancements in chronic inflammatory polyneuropathies offer effective treatments like immunosuppressants and immunoglobulins. Research explores antibody mechanisms beyond demyelination, aiding in diagnosis and treatment strategies for these nerve disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.

Journal of neurology·2022
Same author

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.

Journal of neurology·2022
Same author

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.

Journal of neurology·2020
Same author

[Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Der Nervenarzt·2018
Same author

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

European journal of neurology·2018
Same author

Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.

Journal of neurology·2016

Area of Science:

  • Neurology
  • Immunology

Background:

  • Chronic inflammatory polyneuropathies (CIPN) present complex diagnostic and therapeutic challenges.
  • Understanding underlying immune mechanisms is crucial for effective management.

Purpose of the Study:

  • To review recent developments in the understanding and treatment of chronic inflammatory polyneuropathies.
  • To discuss cell- and antibody-mediated mechanisms in CIPN, referencing experimental autoimmune neuritis.
  • To differentiate idiopathic CIPN from related neuropathies associated with monoclonal gammopathies or malignancies.

Main Methods:

  • Literature review of recent studies on chronic inflammatory polyneuropathies.
  • Analysis of cell- and antibody-mediated pathogenic mechanisms.
  • Comparison of clinical features and treatment responses across different CIPN subtypes.

Related Experiment Videos

Main Results:

  • Effective treatments for CIPN include immunosuppressive agents, plasmapheresis, high-dose intravenous immunoglobulins, and interferon-beta.
  • Antibodies targeting peripheral nervous system antigens can affect nerve function through non-demyelinating mechanisms.
  • Distinctive clinical features and treatment responses support separating idiopathic CIPN from other related polyneuropathies.

Conclusions:

  • Chronic inflammatory polyneuropathies are increasingly treatable with a range of immunomodulatory therapies.
  • Antibody-mediated mechanisms play a significant role in CIPN pathogenesis, extending beyond demyelination.
  • Maintaining distinct classifications for CIPN subtypes is clinically valuable for tailored treatment approaches.